2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Clinical Procedures, Treatment Considerations, Supportive Care, Biological Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Adverse Events, Artificial Intelligence (AI), Natural Language Processing, Biological Processes, Microbiome, Clinical Practice (Health Services and Quality), Practice Models, Quality Improvement, Quality of Care, Diseases, Bone Marrow Failure Syndromes, Aplastic Anemia, Hemoglobinopathies, Sickle Cell Disease, Thalassemia, Immunology, GVHD, Infectious Diseases, Viral, Bacterial, Fungal, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, MPN, Clinical Research, Clinical Trials, Real-World Evidence, Registries, Study Population, Human, Adult
PAPER

2432 Baseline hepatic vulnerability and prior blinatumomab exposure predict sinusoidal obstruction syndrome following allogeneic hematopoietic cell transplantation after inotuzumab ozogamicin for acute lymphoblastic leukemia

Issa F. Khouri, MD, Hagop Kantarjian, MD2, Denai Milton3, Fadi G. Haddad, MD4, Celina Ledesma5, Susan Y. Wu, MD6, Nicholas Short, MD7, Tapan Kadia I, MD8, David Marin9, Warren Fingrut, MD, MPH10, Chitra Hosing, MD11, Partow Kebriaei, MD12, Muzaffar Qazilbash, MD13, Uday Popat, MD, MBA14, Rohtesh Mehta, MD, MPH15, Jin Im, MD, PhD16, Jeremy Ramdial, MD17, Richard Champlin18, Bouthaina S. Dabaja, MD19, Rebecca Garris20, Elias Jabbour, MD21, Alison Gulbis, PharmD22
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
10 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
11 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
12 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
13 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
14 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
15 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
16 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
17 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
18 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
19 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
20 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
21 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
22 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Background

Inotuzumab ozogamicin (INO) is highly effective in relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) but increases the risk of sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) following allogeneic hematopoietic cell transplantation (alloHCT). We evaluated predictors of post-transplant SOS/VOD in adults undergoing alloHCT after INO.

Methods

We retrospectively analyzed 91 adults with B-cell ALL who underwent a first alloHCT after INO between January 2017 and November 2025. SOS/VOD was diagnosed and graded according to 2023 EBMT criteria. Baseline hepatic/VOD risk factors included abnormal pre-transplant hepatic imaging findings, including steatosis or parenchymal abnormalities identified by ultrasound, elastography, or other imaging modalities, known liver disease, and ≤28 days from the last INO dose to alloHCT. Cox proportional hazards models identified factors associated with time to SOS/VOD.

Results

Median age was 33 years (range, 18–72); 41% had HCT-CI ≥3, 51% had high-risk molecular/cytogenetic features, 33% had received ≥3 prior lines of therapy, and 15% prior CAR T-cell therapy. Blinatumomab was administered before alloHCT in 82%, including 46% sequentially, 18% with INO, and 19% using other schedules.

Conditioning consisted of reduced-intensity fludarabine/melphalan (FM)-based regimens in 48%, myeloablative busulfan-based regimens in 33%, and myeloablative TBI/etoposide in 19%. Median age was 44.5, 28.9, and 24.6 years, respectively (P<0.001), and HCT-CI >3 was present in 54.5%, 26.7%, and 29.4% (P=0.025). FM was preferentially selected for patients at increased hepatic or transplant-related risk, including greater comorbidity, baseline hepatic abnormalities, prior intensive therapies, and selected protocols incorporating low-dose INO into conditioning (n=5). The single patient with prior SOS/VOD received FM and had no recurrence.

After a median follow-up of 20.2 months, SOS/VOD developed in 14 patients (15%); 13 of 14 events (93%) were grade ≥3, including 4 fatal grade 5 events. SOS/VOD incidence was 11.4% after FM, 23.3% after busulfan-based conditioning, and 11.8% after TBI-based conditioning (P=0.78). Median cumulative INO dose was similar in patients with and without SOS/VOD (1.4 [range, 0.6–2.7] vs 1.5 mg/m² [range, 0.6–4.3]; P=0.11), as was the median interval from last INO dose to conditioning (57 vs 74 days; P=0.46). Donor type, GVHD prophylaxis, and HCT-CI were not associated with SOS/VOD. Abnormal pre-transplant hepatic imaging findings, most commonly steatosis and parenchymal abnormalities, were strongly associated with SOS/VOD (50% vs 9%; P<0.001), and SOS/VOD increased with baseline hepatic/VOD risk-factor burden (P=0.003).

SOS/VOD incidence was 7.1% with sequential blinatumomab, 6.3% with blinatumomab plus INO, and 17.6% with other schedules. In univariable analysis, sequential blinatumomab had the strongest association with lower SOS/VOD risk (P=0.002), followed by combination therapy (P=0.038); other schedules were not significant (P=0.11). On multivariable analysis, abnormal hepatic imaging findings alone versus no baseline hepatic/VOD risk factors remained independently associated with SOS/VOD (HR, 7.49; 95% CI, 2.22–25.25; P=0.001). Abnormal imaging plus an interval of ≤28 days from the last INO dose to alloHCT was associated with increased risk but did not reach significance (HR, 4.32; 95% CI, 0.79–23.74; P=0.09). Prior blinatumomab exposure remained independently protective (HR, 0.15; 95% CI, 0.05–0.44; P<0.001).

Conclusions

Among adults with B-cell ALL undergoing alloHCT after INO, abnormal pre-transplant hepatic imaging findings were the principal independent risk factor for SOS/VOD, whereas prior blinatumomab exposure was independently associated with markedly lower risk. Although FM was preferentially selected for patients at greater hepatic or transplant-related risk, SOS/VOD incidence was numerically lower with FM than with busulfan-based conditioning and comparable to TBI-based conditioning. These findings support pre-transplant hepatic assessment, risk-adapted conditioning, and thoughtful treatment sequencing to mitigate SOS/VOD risk.

Issa F. Khouri, MD: No relevant conflicts of interest to declare.